To study the prevalence of vitamin D deficiency in pregnant women and the effect of supplementation in preventing adverse pregnancy outcome

Vitamin D deficiency in pregnancy: Its prevalence and role of supplementation in preventing adverse maternal and fetal outcome: A double blind randomized placebo-controlled trial.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/10/004056

Enrollment

280

Registered

2013-10-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Vitamin D deficiency Maternal problems : preeclampsia, gestational diabetes mellitus, gall bladder dysfunction Fetal problems: intra uterine growth restriction

Interventions

Intervention1: vitamin D (cholecalciferol): 60000IU/d to be taken with a glass of milk for 5 days Control Intervention1: Identical looking Placebo (Starch): Identical looking Placebo to be taken with

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Singleton pregnancy normotensive

Exclusion criteria

Exclusion criteria: ?Pre- existing medical conditions like rheumatoid arthritis, thyroid, parathyroid or adrenal diseases, hepatic or renal failure, metabolic bone disease, diabetes mellitus, malabsorption, essential hypertension ?Medications influencing bone, vitamin D or calcium metabolism ?Preexisting gall bladder disease

Design outcomes

Primary

Measure	Time frame
Incidence of Gestational Diabetes Mellitus Preeclampsia Gall bladder dysfunction Intra Uterine Growth Restriction Timepoint: Through pregnancy delivery	—

Secondary

Measure	Time frame
Prevalence of vitamin D deficiency Effect of vitamin D supplementation on labor and delivery period of gestation at delivery duration of labor mode of delivery post partum complications Neonatal outcome apgar score birth weight small for gestational age head circumference NNN admission ? length of the newborn Timepoint: During labor and delivery and postnatal	—

Countries

India

Contacts

Public ContactRimpi Singla

Deptt of Obstetrics and Gynaecology, PGIMER

chddialysis@rediffmail.com01722756345

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026